Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

“Gilead’s restrictions on access to lenacapavir could allow the HIV epidemic to spread. This is the closest we have ever been ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...